Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > Knowledge & support > Resource hub > Teplizumab is just the beginning
Dr Besser is leading a study investigating how to introduce screening for type 1 diabetes in children into the NHS.
I was diagnosed with type 1 diabetes when I was nine. That’s when I decided I was going to be a paediatrician and look after children with diabetes. It is very exciting that we now have teplizumab, a disease-modifying drug with the potential to push diabetes into adulthood and give children back their childhood. No parent wants their child to have type 1, so anything that delays diabetes onset is a good thing.
One benefit to delaying the onset of type 1 is that it allows time for your pancreas to grow and develop more. The bigger your pancreas is, the more insulin-producing cells you have, so the longer it takes for the immune system to destroy them. This means that people diagnosed at an older age can sometimes keep making small amounts of insulin. Any amount of insulin that the body can still make can help with type 1 diabetes management by providing a buffer against severe hypoglycemia and long-term complications of diabetes.
If the MHRA, who license new drugs in the UK, approves teplizumab, we need to know who to give it to. We don’t currently have a process of identifying who would benefit from teplizumab. That’s where screening comes in.
We are running a feasibility study called T1 Early to find out if we can screen children for type 1 diabetes when they have their pre-school vaccinations at age three or four. We are testing children’s blood for immune markers which are a sign that the pancreas’ insulin-producing cells are being attacked. A child with two or more forms of these immune markers is very likely to develop type 1 in childhood, and certainly in their lifetime.
Screening children is a balance of risk and harm. There can be a long period between being identified as high risk of type 1 and needing insulin. While we can educate people about type 1 before their diagnosis, we are wary of the anxiety and medical monitoring it may bring. But now there’s a treatment that we can use to delay type 1, it reduces that anxiety and offers an extra benefit to screening.
But it doesn’t end with screening. The NHS, rather than a research programme, will need to deliver teplizumab if it is licensed. So, we need to be ready with the infrastructure in place for when we can identify a child is at high risk and know how to follow them up and support them. Early identification of type 1 will also have the benefit of stopping children becoming seriously unwell or dying due to a late or missed diagnosis. In paediatric diabetes we are currently only funded to look after children who take insulin. There’s nothing in place for children who don’t yet have type 1. We need to teach healthcare professionals this new specialism of pre-clinical type 1 diabetes.
I have a grant from the NIHR (the research arm of the NHS) and Novo Nordisk Research Foundation to determine how we integrate screening and follow-up into clinical care. I’m looking at its cost effectiveness as well as willingness in the general population to screen. I am setting up an NHS healthcare professional group to advise how to deliver screening and teplizumab. We are also interviewing parents in the T1 Early screening programme and getting feedback from people who turned it down, to better understand their experience. This project has already started, and we expect our first results in December.
People with diabetes have been waiting a long time for a therapy to delay type 1. The approval of teplizumab is the beginning of a journey. It paves the way for multiple drugs to emerge that can help delay and ultimately prevent type 1. We’ve had a hundred years of insulin. It’s time for a hundred years of immune therapies.
Teplizumab, the world’s first type 1 diabetes disease-modifying drug, has been approved by the USA’s Food and Drug Administration (FDA).
Read answers to frequently asked questions about teplizumab
The ELSA Study will provide crucial insights into practical and effective ways to screen large numbers of children in the UK for type 1 diabetes.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.